Breaking with past comments, FDA's Richard Pazdur telegraphs rough road ahead for Lilly's China-developed cancer drug

Max Gelman

Senior Editor

The biopharma industry has recently seen a groundswell of companies attempting to get their cancer drugs approved using data from China, namely Eli Lilly and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Breaking with past comments, FDA's Richard Pazdur telegraphs rough road ahead for Lilly's China-developed cancer drug

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Senate Judiciary Committee advances patent bill with new protections for pharma challenges

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Break­ing with past com­ments, FDA's Richard Paz­dur telegraphs rough road ahead for Lil­ly's Chi­na-de­vel­oped can­cer drug

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Breaking with past comments, FDA's Richard Pazdur telegraphs rough road ahead for Lilly's China-developed cancer drug

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Senate Judiciary Committee advances patent bill with new protections for pharma challenges

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration